Actively Recruiting

Phase 2
Phase 3
Age: 0Minutes - 96Hours
All Genders
ID06897839

Randomized, Double-Blind, Adaptive Phase 2b/3 Study of Zelpultide Alfa to Prevent Bronchopulmonary Dysplasia in High-Risk Preterm Neonates

Led by Airway Therapeutics, Inc. · Updated on 2026-06-03

366

Participants Needed

50

Research Sites

108 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying if an investigational drug called Zelpultide Alfa can reduce the risk of Bronchopulmonary Dysplasia (BPD) in extremely premature babies. This is a randomized, double-blind, placebo-controlled, multicenter phase 2b/3 trial with an adaptive design to evaluate the drug's safety and effectiveness in this vulnerable population. The study includes two parts: the first part focuses on selecting the best dose and exploring initial effects, while the second part confirms the chosen dose's impact on BPD and death rates. In Part 1, participants are randomly assigned to receive either Zelpultide Alfa at 4 mg/kg, 6 mg/kg, or a placebo (air-sham), all along with standard care. Treatment is given intratracheally up to seven times at 24-hour intervals while the babies are still intubated. After deciding on the best dose from Part 1, Part 2 compares the selected Zelpultide Alfa dose with placebo, again alongside standard care, using a 1:1 random assignment. The main goal in Part 2 is to confirm whether adding Zelpultide Alfa reduces the incidence of moderate to severe BPD or death. Participants will be closely monitored with various safety and efficacy assessments throughout the study. Researchers will measure outcomes like the occurrence of grade 2 or 3 BPD or death by 36 weeks post menstrual age, days without ventilator support, oxygen use, and hospitalization rates up to 24 months corrected age. The study also tracks adverse events and immune responses. Participation involves receiving study treatments while intubated and attending follow-up evaluations to assess the drug's effects and safety over time.

CONDITIONS

Brief Title

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

Who Can Participate

Age: 0Minutes - 96Hours
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Born between gestational age 22 0/7 to 27 6/7 weeks, inclusive
  • Received at least one dose of animal-derived pulmonary surfactant treatment after birth
  • Intubated and on invasive mechanical ventilation as part of standard care
  • Able to receive first dose of study drug or placebo at least 15 minutes after surfactant administration but within 96 hours of birth and 48 hours from start of ventilation
  • Informed consent signed by parent(s) or legal guardian(s)
Not Eligible

You will not qualify if you...

  • Birth weight less than 400 grams or greater than 1,500 grams
  • Major congenital abnormalities impacting heart or lung function such as Potter-like syndrome, diaphragmatic hernia, omphalocele, gastroschisis, esophageal atresia, or cyanotic congenital heart disease
  • Active do not resuscitate (DNR) order in place
  • History of allergy or sensitivity to surfactant or study drug components
  • Participation in other clinical studies with investigational treatments within 30 days before birth or up to 36 weeks post menstrual age
  • Any condition judged by investigator to put neonate at significant risk or interfere with study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 7 days

Participants receive up to 7 administrations of Zelpultide alfa or placebo via intratracheal administration at 24-hour intervals while intubated, alongside standard of care.

Up to 7 dosing visits (in-person) during intubation

Follow-up

Duration - Up to 24 months corrected age

Participants are monitored for safety, lung function, and developmental outcomes through 36 weeks post menstrual age and up to 24 months corrected age.

Multiple follow-up visits including assessments at 36 and 40 weeks post menstrual age, and at 6, 12, and 24 months corrected age

Trial Site Locations

Total: 50 locations

1

Clínica y Maternidad Suizo Argentina

Buenos Aires, Argentina

Actively Recruiting

2

Hospital Italiano de Buenos Aires

Buenos Aires, Argentina

Actively Recruiting

3

Hospital Sanatorio de la Trinidad San Isidro

Buenos Aires, Argentina

Not Yet Recruiting

4

Hospital Universitario Austral

Buenos Aires, Argentina

Actively Recruiting

5

ZAS Middelheim

Antwerp, Belgium

Not Yet Recruiting

6

Cliniques Universitaires Saint-Luc

Brussels, Belgium

Not Yet Recruiting

7

UZ Leuven

Leuven, Belgium

Not Yet Recruiting

8

CHU de Liege - Hospital de la Citadelle

Liège, Belgium

Not Yet Recruiting

9

Clinique CHC MontLégia

Liège, Belgium

Actively Recruiting

10

CHU Lille - Hôpital Jeanne de Flandre

Lille, France

Actively Recruiting

11

CHRU Nancy

Nancy, France

Actively Recruiting

12

CHU Nice

Nice, France

Not Yet Recruiting

13

AP-HP CHU Robert-Debré - Hôpitaux de Paris

Paris, France

Actively Recruiting

14

AP-HP Paris Saclay University - Hôpitaux Antoine-Béclère

Paris, France

Actively Recruiting

15

AP-HP Paris Saclay University Bicêtre Hospital

Paris, France

Actively Recruiting

16

AP-HP University Hospital Cochin - Port Royal

Paris, France

Actively Recruiting

17

Hôpital de Poissy Saint-Germain-en-Laye

Poissy, France

Actively Recruiting

18

Medical Faculty of TU Dresden

Dresden, Germany

Not Yet Recruiting

19

Universitätsklinikum Freiburg

Freiburg im Breisgau, Germany

Not Yet Recruiting

20

University Children's Hospital Regensburg (KUNO)

Regensburg, Germany

Actively Recruiting

21

Bnai Zion Medical Center

Haifa, Israel

Not Yet Recruiting

22

Rambam Medical Center

Haifa, Israel

Actively Recruiting

23

Haddasah medical center

Jerusalem, Israel

Not Yet Recruiting

24

Shaare-Zedek Medical Center

Jerusalem, Israel

Actively Recruiting

25

Ziv Medical Center

Safed, Israel

Actively Recruiting

26

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

Bologna, Italy

Actively Recruiting

27

Istituto Giannina Gaslini

Genova, Italy

Not Yet Recruiting

28

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

Actively Recruiting

29

Ospedale dei Bambini "V. Buzzi"

Milan, Italy

Actively Recruiting

30

Università degli Studi di Napoli Federico II

Naples, Italy

Actively Recruiting

31

Azienda Ospedale Università di Padova

Padova, Italy

Actively Recruiting

32

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland

Not Yet Recruiting

33

University Hospital in Krakow

Krakow, Poland

Not Yet Recruiting

34

Polish Mother's Memorial Hospital - Research Institute in Lodz

Lodz, Poland

Not Yet Recruiting

35

Gynecological Obstetric Clinical Hospital of Poznan University of Medical Sciences

Poznan, Poland

Actively Recruiting

36

University Clinical Hospital No. 2 PUM

Szczecin, Poland

Not Yet Recruiting

37

University Hospital Wroclaw

Wroclaw, Poland

Actively Recruiting

38

Hospital General Universitario de Alicante Dr. Balmis

Alicante, Spain

Actively Recruiting

39

Hospital Clínic de Barcelona

Barcelona, Spain

Actively Recruiting

40

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Actively Recruiting

41

Hospital Sant Joan de Déu

Barcelona, Spain

Actively Recruiting

42

Hospital Universitario Cruces - OSI Ezkerraldea-Enkarterri-Cruces

Bilbao, Spain

Actively Recruiting

43

Hospital Universitario Puerta del Mar

Cadiz, Spain

Actively Recruiting

44

Hospital Universitari Arnau de Vilanova de Lleida

Lleida, Spain

Actively Recruiting

45

Hospital General Universitario Gregorio Marañón

Madrid, Spain

Not Yet Recruiting

46

Hospital Universitario La Paz

Madrid, Spain

Actively Recruiting

47

Hospital Regional Universitario de Málaga

Málaga, Spain

Actively Recruiting

48

Hospital Clínico Universitario de Santiago

Santiago de Compostela, Spain

Actively Recruiting

49

Hospital Universitari i Politècnic La Fe

Valencia, Spain

Actively Recruiting

50

Hospital Universitario Miguel Servet

Zaragoza, Spain

Actively Recruiting

Loading map...

Research Team

A

Alan Wolk

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Similar Trials

A Phase 2b Study Evaluating OHB-607 Compared to Standard Neo...

Bronchopulmonary Dysplasia

Actively Recruiting

66 locations

Crossover Study of Work of Breathing With Different BiPAP Pr...

Bronchopulmonary Dysplasia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here